Recent US-China Tariff War: Opportunities for Indian Pharmaceutical Exports?

Chakraborty, Debashis and Maheshwari, Sourabh and Parashar, Sushil (2018): Recent US-China Tariff War: Opportunities for Indian Pharmaceutical Exports?

Abstract

The inception of World Trade Organization (WTO) in 1995 was expected to reduce trade barriers across member countries on one hand and facilitate growth though promotion of international trade in merchandise products and services on the other. The subsequent WTO-led reforms deepened the globalization wave. In recent times however, the world is witnessing a phase of ‘de-globalization’, with rise in trade barriers and inwardness. The recent increase in US tariffs on Chinese exports and countermeasures imposed by China are a case in point. In 2014 India has initiated the Make-in-India scheme for deepening industrialization and facilitating exports. The current paper evaluates the possible opportunities for expanding Indian pharmaceutical exports in the US market, given the increase in tariff against Chinese products with the help of select trade indices. The analysis portrays a modest opportunity for Indian pharmaceutical exports in the US market, based on their past performance. Only six products at HS 6-digit level, based on the six indicators, are found to be enjoying competitiveness in the US market. The paper concludes that facilitating R&D in pharma segment as well as expanding the coverage of mutual recognition of standards in US may be explored as possible steps for enhancing Indian exports.

• Item Type: MPRA Paper
• Language: English
• Keywords: India, US, Pharmaceutical trade, Trade indices, Trade policy, Make in India
• Subjects: F - International Economics > F1 - Trade > F10 - General; F - International Economics > F1 - Trade > F13 - Trade Policy ; International Trade Organizations

References

ASSOCHAM (2016), ‘IPR in pharmaceuticals: Balancing, innovation and access’, Available at: http://www.assocham.org/newsdetail.php?id=5886 (accessed October 12, 2018).

Baldwin, R. (2014), ‘Reconciling Regionalism and Multilateralism in a Post-Bali World Multilateralising 21ST Century Regionalism’, Global Forum on Trade, 11-12 February, OECD Conference Centre, Paris.

Baldwin, R. and Evenett, S. (eds.) (2009), ‘The collapse of global trade, murky protectionism, and the crisis: Recommendations for the G20’, London: Centre for Economic Policy Research.

Bouët, A. and Laborde, D. (2017), ‘US Trade Wars with Emerging Countries in the 21st Century: Make America and Its Partners Lose Again’, IFPRI Discussion Paper 01669, Washington DC: International Food Policy Research Institute (IFPRI).

Capital Trade Incorporated (undated), ‘An Assessment of China’s Subsidies to Strategic and Heavyweight Industries’, submitted to the U.S.-China Economic and Security Review Commission, Washington DC: CTI.

Chakraborty, D. (2018), ‘Picking the Right Alternative: Should India participate in TPP instead of RCEP?’, in J. Chaisse, H. Gao and C. Lo (eds.), The Transpacific Partnership: A Paradigm Shift in International Trade Regulation, pp. 501-519, Singapore: Springer.

Deeds, C. and Whiteford, S. (undated), ‘The Social and Economic Costs of Trump’s Wall’, Voice of Mexico, Available at: http://www.revistascisan.unam.mx/Voices/pdfs/10207.pdf (accessed October 12, 2018).

DW (2018), ‘China retaliates after US imposes new $200 billion tariffs’, Available at: https://www.dw.com/en/china-retaliates-after-us-imposes-new-200-billion-tariffs/a-45532375 (accessed October 12, 2018).

Economic Times (2016), ‘In 6 years, US FDA rejected 13,000 Indian products’, February 9, New Delhi.

Federation of Indian Chambers of Commerce & Industry (2015), ‘Realising “Make in India” – Journey to become the most preferred manufacturer of high quality affordable medicines’, Available at: http://ficci.in/spdocument/20712/Final-Realizing-Make-in-India-Vision.pdf (accessed October 12, 2018).

Fergusson, I. F. (2011), ‘World Trade Organization Negotiations: The Doha Development Agenda’, Document No. RL32060, Washington DC: Congressional Research Service.

Government of India (2018), ‘Progress Under 'Make in India' Programme’, Unstarred Question No. 1631, Rajya Sabha, Available at: http://dipp.nic.in/sites/default/files/ru_1631.pdf (accessed October 12, 2018).

Government of India (2017), ‘Public Procurement (Preference to make in India) Order 2017’, Available at: http://dipp.nic.in/sites/default/files/publicProcurement_MakeinIndia_15June2017.pdf (accessed October 12, 2018).

Government of India (2015), ‘India’s Foreign Trade Policy 2015-2020’, Available at: http://dgft.gov.in/policies/foreign-trade-policy (accessed October 12, 2018).

Government of India (2011a), ‘National Manufacturing Policy’, New Delhi: Department of Industrial Policy and Promotion, Ministry of Commerce and Industry.

Government of India (2011b), ‘Boosting India’s Manufacturing Exports’, Report of the Working Group to Planning Commission, New Delhi: Department of Commerce, Ministry of Commerce and Industry.

Government of India (undated), ‘Make-in-India’, Available at: http://www.makeinindia.com/home/ (accessed October 12, 2018).

Helble, M. (2017), ‘Salvaging the Trans-Pacific Partnership: Building Blocks for Regional and Multilateral Trade Opening?’, ADBI Working Paper Series No. 695, Tokyo: Asian Development Bank Institute.

Horn, H., Mavroidis, P. C. and Sapir, A. (2009), ‘Beyond the WTO? An anatomy of EU and US preferential trade agreements’, Bruegel Blueprint Series Volume VII, Brussels: Bruegel.

India Brand Equity Foundation (2018), ‘Indian Pharmaceuticals Industry Analysis’, Available at: https://www.ibef.org/industry/pharmaceutical-india.aspx (accessed October 12, 2018).

India Brand Equity Foundation (2015), ‘Pharmaceuticals, Available at: https://www.ibef.org/download/Pharmaceuticals-March-2015.pdf (accessed October 12, 2018).

International Federation of Pharmaceutical Manufacturers & Associations (2017), ‘The Pharmaceutical Industry and Global Health: Facts and Figures 2017’, Available at: https://www.ifpma.org/wp-content/uploads/2017/02/IFPMA-Facts-And-Figures-2017.pdf (accessed October 12, 2018).

International Monetary Fund (2018), ‘World Economic Outlook 2018: Cyclical Upswing, Structural Change’, Washington DC: IMF.

International Trade Centre. (undated). Trade Map. Available at: http://www.trademap.org/Index.aspx (accessed October 12, 2018).

James, H. (2017), ‘Deglobalization as a Global Challenge’, CIGI Papers No. 135, Waterloo: Centre for International Governance Innovation (CIGI).

Joseph, R. K. (2011), ‘The R&D Scenario in Indian Pharmaceutical Industry’, RIS Discussion Paper No. 176, New Delhi: Research and Information System for Developing Countries (RIS).

Kallummal, M. and Bugalya, K. (2012), ‘Trends in India’s Trade in Pharmaceutical Sector: Some Insights’, Available at: http://wtocentre.iift.ac.in/workingpaper/Working%20Paper2.pdf (accessed October 12, 2018).

Lim, L. (2018), ‘Trump’s Protectionism: Method to the Madness?’, RSIS Commentary No. 47, Singapore: S. Rajaratnam School of International Relations (RSIS), Nanyang Technological University.

Lincicome, S. (2017), ‘Doomed to Repeat It: The Long History of America’s Protectionist Failures’, Cato Policy Analysis No. 819, Washington DC: Cato Institute.

Neufeld, N. (2014), ‘Trade Facilitation Provisions in Regional Trade Agreements: Traits and Trends’, Staff Working Paper ERSD‐2014‐01, Geneva: Economic Research and Statistics Division, World Trade Organization (WTO).

Phadnis, A. (2017), ‘Another US warning on Indian drugs’, February 25, Mumbai: Business Standard.

PricewaterhouseCoopers (2010), ‘Global pharma looks to India: Prospects for growth’, London: PWC.

Shepherd, B. (2016), ‘Trade Facilitation and Global Value Chains: Opportunities for Sustainable Development’, Geneva: International Centre for Trade and Sustainable Development (ICTSD).

Stiglitz, J. E. (1987), ‘The Causes and Consequences of the Dependence of Quality on Price’, Journal of Economic Literature, 25(1): 1-48.

United States Trade Representative (2018), ‘Notice of Determination and Request for Public Comment Concerning Proposed Determination of Action Pursuant to Section 301: China’s Acts, Policies, and Practices Related to Technology Transfer, Intellectual Property, and Innovation’, Docket No. USTR-2018-0005, Available at: https://ustr.gov/sites/default/files/files/Press/Releases/301FRN.pdf (accessed October 12, 2018).